Effect of Calcium Carbonate for Reduction of Serum Fibroblast Growth Factor 23 (FGF 23) in Chronic Kidney Disease Stage 3

Dietary Phosphorus Control versus Combination of Diet and Calcium Carbonate as Phosphate Binder Therapy for Reduction of Serum Fibroblast Growth Factor 23 (FGF 23) in Chronic Kidney Disease Stage 3

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20150220001

Enrollment

Registered

2015-02-20

Start date

2014-02-19

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease stage 3 chronic kidney disease stage 3 calcium carbonate phosphate binder Fibroblast growth factor 23

Interventions

Calcium carbonate 350 mg orally thice a day with meal plus phosphate diet restriction,Calcium carbonate 700 mg orally thrice a day with meal plus diet phosphate restriction,Diet phosphate restriction

Experimental Drug,Experimental Drug,Placebo Comparator Behavioral

Calcium carbonate 350 mg,Calcium carbonate 700 mg,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Chronic kidney disease stage 3 defined by estimated GFR using CKD-EPI formula Age >18 years old FGF-23 > 100 RU/mL

Exclusion criteria

Exclusion criteria: 1. Serum albumin corrected calcium > 9.6 mg/dL or serum phosphate > 4.5 mg/dL or intact PTH > 65 pg/mL 2. History of symptomatic hypocalcemia 3. History of calculi in genitourinary system 4. Primary hyperparathyroidism 5. History of thyroidectomy, parathyroidectomy, or radiation of head and neck 6. Patients prescribed drugs interfering vitamin D and/or bone metabolism, for example, corticosteroids, phenytoin, calcimimetics, calcineurin inhibitor, etc. 6. Patients diagnosed osteoporosis and treated with bislphosphonates and/ or estrogen derivatives 7. Pregnancy

Design outcomes

Primary

Measure	Time frame
FGF23 9 months pg/mL by Human FGF-23 (C-Term) ELISA Kit (Immunotopic, CA, USA)	—

Secondary

Measure	Time frame
hypercalcemia 9 months mg/dL	—

Contacts

Public ContactKraiwiporn Kiattisunthorn

Mahidol University

kraiwiporn.kia@mahidol.ac.th+6624198383

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026